Kimberly Van Deventer

2601 – 588 Broughton Street Vancouver, British Columbia V6G 3E3

EARLY WARNING NEWS RELEASE

Vancouver, British Columbia, August 2, 2018, Kimberly Van Deventer ("Ms. Van Deventer"), a shareholder of PreveCeutical Medical Inc. (the "Issuer"), makes the following announcement in accordance with National Instrument 62-103 *The Early Warning System and Related Take Over Bids* and National Instrument 62-104 *Take-Over Bids and Issuer Bids*.

Ms. Van Deventer advises that on August 2, 2018, she acquired ownership and control of 1,500,000 common shares in the capital of the Issuer, at a deemed issuance price of \$0.035 per share (the "**Acquisition**"). The common shares of the Issuer (the "**Shares**") are listed for trading on the Canadian Securities Exchange.

Immediately before the completion of the Acquisition, Ms. Van Deventer owned 35,000,000 Shares, 500,000 stock options (exercisable within 60 days), and is a party to certain convertible credit facilities with the Issuer, pursuant to which she has the option to convert the outstanding balance to an aggregate of 45,733,600 Shares. As a result of the Acquisition, Ms. Van Deventer beneficially owns and controls 36,500,000 Shares, together with her abovenoted convertible securities, representing approximately 9.3% (18.99% on a partially diluted basis) of the currently issued and outstanding Shares.

Ms. Van Deventer acquired the Shares for investment purposes only. However, Ms. Van Deventer will review her holdings from time to time and may, in the future, increase or decrease her ownership or control over securities of the Issuer as circumstances dictate.

An early warning report will be filed under the Issuer's profile on the SEDAR website at <u>www.sedar.com</u>. A copy of the early warning report can also be obtained from the contact below.

The Issuer's head office is located at Suite 2200, 1177 West Hastings Street, Vancouver, British Columbia, V6E 2K3.

For more information contact:

Kimberly Van Deventer (604) 505-2204